[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebellum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebellum":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,72,103,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100551289","imaging-speech-in-neurotypical-adults-and-individuals-with-cerebellar-stroke-100551289",false,"NCT06458153","Imaging Speech in Neurotypical Adults and Individuals With Cerebellar Stroke","High-resolution Functional Imaging of Speech-induced Sensory Modulation","Inclusion Criteria:\n\nCohort 1 (neurotypical adults):\n\n* Age 18-49\n* Right-handed\n* Native English speaker\n\nCohort 2 (people with cerebellar lesions):\n\n* Age 18 or older\n* Right-handed\n* Native English speaker\n* History of cerebellar stroke\n\nCohort 3 (controls matched to Cohort 2)\n\n* Age 18 or older\n* Right-handed\n* Native English speaker\n\nExclusion Criteria:\n\nCohort 1 (neurotypical adults):\n\n* Presence of MRI risk factors: metal and\u002For electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant\n* History of neurological \u002F neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury)\n* Hearing loss, defined by pure tone thresholds \\>25 decibels (dB) hearing level (HL) at octave frequencies between 250-8000 Hz\n* Clinical diagnosis and\u002For treatment for schizophrenia or other psychotic disorders\n* Clinical diagnosis and\u002For treatment for neurocognitive disorders (e.g., dementia, delirium)\n* Presence of a severe and unmanaged, clinically diagnosed attention disorder\n* Clinically diagnosed with or treated for a speech, language, or hearing disorder\n* Head circumference greater than 60cm or weight greater than 300 pounds\n* History of severe claustrophobia\n* Currently pregnant\n\nCohort 2 (people with cerebellar lesions):\n\n* Presence of MRI risk factors: metal and\u002For electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant\n* History of neurological \u002F neurodegenerative disease or severe brain injury other than stroke\n* Hearing loss, defined by pure tone thresholds \\>50 dB HL at octave frequencies between 250-4000 Hz\n* Clinical diagnosis and\u002For treatment for schizophrenia or other psychotic disorders\n* Clinical diagnosis and\u002For treatment for neurocognitive disorders (e.g., dementia, delirium)\n* Presence of a severe and unmanaged, clinically diagnosed attention disorder\n* Head circumference greater than 60cm or weight greater than 300 pounds\n* History of severe claustrophobia\n* Currently pregnant\n\nCohort 3 (controls matched to Cohort 2):\n\n* Presence of MRI risk factors: metal and\u002For electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant\n* History of neurological \u002F neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury)\n* Hearing loss, defined by pure tone thresholds \\>50 dB HL at octave frequencies between 250-4000 Hz\n* Clinical diagnosis and\u002For treatment for schizophrenia or other psychotic disorders\n* Clinical diagnosis and\u002For treatment for neurocognitive disorders (e.g., dementia, delirium)\n* Presence of a severe and unmanaged, clinically diagnosed attention disorder\n* Clinically diagnosed with or treated for a speech, language, or hearing disorder\n* Head circumference greater than 60cm or weight greater than 300 pounds\n* History of severe claustrophobia\n* Currently pregnant",true,"ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this research study is to learn how the brain areas that plan and control movement interact with the areas responsible for hearing and perceiving speech in healthy adults and people who have had cerebellar strokes. The main questions it aims to answer are:\n\n1. What regions of the brain's sensory systems show changes in their activity related to speech?\n2. To what extent do these regions help listeners detect and correct speech errors?\n3. What is the role of the cerebellum (a part of the brain in the back of the head) in these activities?\n\nParticipants will be asked to complete several experimental sessions involving behavioral speech and related tests and non-invasive brain imaging using electroencephalography (EEG) and functional magnetic resonance imaging (fMRI).",[27,28],"Stroke","Cerebellum",[30,31,32,33,34,35],"fmri","speech production","cerebellum","auditory-motor integration","speech motor control","neuroimaging","RECRUITING","2026-06-16",{"date":39,"type":40},"2026-06-18","ACTUAL",{"date":42,"type":40},"2025-05-27",{"date":44,"type":21},"2028-07",{"name":46,"class":47},"University of Pittsburgh","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100512040","examining-lateralized-aspects-of-motor-control-using-non-invasive-neural-stimulation-100512040","NCT05947279","Examining Lateralized Aspects of Motor Control Using Non-invasive Neural Stimulation","Inclusion Criteria:\n\n* Right-handed as determined by the short-form Edinburgh Handedness Inventory\n* Between the ages of 18 and 40\n\nExclusion Criteria:\n\n* Mixed- or left-handed as determined by the short-form Edinburgh Handedness Inventory\n* Self-reported history of any of the following:\n\nSeizure and\u002For diagnosis of epilepsy Fainting spells Concussion with loss of consciousness Ringing in the ears (tinnitus) Cochlear implants Migraines Diagnosed psychological or neurological condition Metal in the scalp\n\n* Any previous adverse reaction to a brain stimulation technique\n* Any previous adverse reaction to 3D virtual reality environments (i.e. 'cybersickness')\n* Possibility of being currently pregnant (for females only)\n* Current open head wound or skin condition of the scalp\n* Current implanted device(s) (i.e. cardiac pacemaker)","40 Years",{"count":57,"type":21},60,[24],"Motor adaptation and generalization are believed to occur via the integration of various forms of sensory feedback for a congruent representation of the body's position in space along with estimation of inertial properties of the limb segments for accurate specification of movement. Thus, motor adaptation is often studied within curated environments incorporating a \"mis-match\" between different sensory systems (i.e. a visual field shift via prism googles or a visuomotor rotation via virtual reality environment) and observing how motor plans change based on this mis-match. However, these adaptations are environment-specific and show little generalization outside of their restricted experimental setup. There remains a need for motor adaptation research that demonstrates motor learning that generalizes to other environments and movement types. This work could then inform physical and occupational therapy neurorehabilitation interventions targeted at addressing motor deficits.",[61,62,28],"Motor Adaptation and Generalization","Posterior Parietal Cortex","2026-03-12",{"date":65,"type":40},"2026-03-13",{"date":67,"type":40},"2024-04-03",{"date":69,"type":21},"2026-08-15",{"name":71,"class":47},"Virginia Commonwealth University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100567514","advantage-of-cerebellar-transcranial-magnetic-stimulation-in-alzheimers-diseases-act-ad-100567514","NCT06669182","Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）","Effects of Cerebellar Transcranial Magnetic Stimulation on Patients With Alzheimer's Disease：A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: 50-85 years old\n2. Meet the core clinical criteria of NIA-AA for possible Alzheimer's disease dementia, and PET or cerebrospinal fluid markers show elevated p-tau and decreased A β (1-42)\n3. MMSE score ranges from 18-26 points; CDR score 0.5-1 points\n4. The patient has received treatment with acetylcholinesterase inhibitors (AChEI), NMDA receptor antagonists, or mannequine therapy, and the current dosing regimen has remained stable for the 12 weeks prior to baseline assessment\n5. At least one adult caregiver\n6. The patient or legal guardian voluntarily signs the informed consent form\n\nExclusion Criteria:\n\n1. Neurodegenerative disorders other than AD.\n2. Significant intracranial focal or vascular pathology seen on brain MRI scan\n3. History of seizure (with the exception of febrile seizures in childhood)\n4. Any of the following psychotic disorders (DSM IV-TR criteria):\n\n   * Major depressive disorder (current)\n   * Schizophrenia\n   * Other psychotic disorders, bipolar disorder, or substance related disorders (within the past 5 years)\n5. GDS score ≥ 8 points in baseline assessment\n6. Cerebrovascular disease, severe infection, malignant tumor, or severe dysfunction of organs such as heart, liver, and kidney.\n7. Pregnant or lactating women\n8. Contraindications for TMS or MRI, metal or implanted devices in the body (such as pacemakers, deep brain stimulators).\n9. Participate in AD related clinical trials within 6 months prior to research registration","50 Years","85 Years",{"count":20,"type":21},[24],"Alzheimer's Disease (AD) is the primary cause of dementia, with its prominent feature being cognitive decline. The cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention. This study will be conducted to evaluate the efficacy and safety of cerebellar Intermittent theta-burst stimulation (CRB-iTBS) in participants with mild Alzheimer's disease on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 3 months of treatment in the Core Study. This project aims to provide a valid treatment to improve the cognitive function and quality of life for those with Alzheimer's disease.",[85,86,28],"Alzheimer Disease","Transcranial Magnetic Stimulation",[88,89,90,91,92],"Transcranial magnetic stimulation","Intermittent theta burst stimulation","Cerebellar cognitive reserve","Default mode network","Alzheimer's disease","2025-11-18",{"date":95,"type":40},"2025-11-24",{"date":97,"type":40},"2025-01-07",{"date":99,"type":21},"2026-04-10",{"name":101,"class":47},"Xijing Hospital",4,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":48},"100587357","phase-4-the-study-on-the-efficacy-of-tdcs-stimulation-of-the-cerebellum-combined-with-xingnaojing-injection-in-patients-with-consciousness-disorders-after-cranial-injury-100587357","NCT06927336","The Study on the Efficacy of tDCS Stimulation of the Cerebellum Combined With XingNaoJing Injection in Patients With Consciousness Disorders After Cranial Injury","Inclusion Criteria:\n\n1. aged 18-80 years;\n2. All patients met the diagnostic criteria of DoC;\n3. more than 1 month after the initial head injury;\n4. stable consciousness for at least 2 weeks before admission (no change in CRS-R total score);\n5. no skull defect or large area of skull repair;\n6. The legal representative authorized by the patient approved the experimental protocol and signed the informed consent form.\n\nExclusion Criteria:\n\n1. supratentorial abnormalities on computed tomography (CT) or magnetic resonance imaging (MRI) involving more than one third of the middle cerebral artery territory;\n2. a life expectancy of less than 3 months or a follow-up of less than 3 months;\n3. retention of intracranial metal objects, cranial debridement, or presence of cranial defects and any clinically significant or unstable medical diseases;\n4. EEG recording with significant muscle artifacts and inhibitory bursts;\n5. nonconvulsive status epilepticus; Periodic or burst rhythms evoked by stimulation;\n6. disturbance of consciousness due to surgical injury or tumor.","80 Years",{"count":111,"type":21},200,[113],"PHASE4","The purpose of this study is to investigate the effect of tDCS stimulation of cerebellum combined with Xingnaojing on patients with disturbance of consciousness after craniocerebral injury, and to clarify the relationship between the following two points: (1) to clarify whether MMN, P300, fNIRS, BAEP, SEP can be used as objective indicators to distinguish VS from MCS. (2) To clarify the changes of consciousness level and brain function in DoC patients with craniocerebral injury treated with tDCS stimulation of cerebellum combined with Xingnaojing.",[116,28,117,118],"tDCS","Brain Injury","Disturbance of Consciousness","NOT_YET_RECRUITING","2025-04-14",{"date":122,"type":40},"2025-04-15",{"date":124,"type":21},"2025-04-25",{"date":126,"type":21},"2026-12-30",{"name":128,"class":47},"The Second Affiliated Hospital of Kunming Medical University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":4},"100574249","effects-of-3-month-melatonin-treatment-on-regional-cerebellar-structure-and-blood-biomarkers-in-alzheimers-disease-spectrum-100574249","NCT06756828","Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spectrum","Study on Regional Structural Changes in the Cerebellum Associated with Blood Biomarkers, Cognitive Decline, and Physical Performance in Alzheimer's Spectrum Patients Following a 3-Month Melatonin Treatment Using Digital Health Technology","Inclusion Criteria:\n\n* Male and female participants aged 60 to 90 years\n* Individuals presenting with cognitive impairment as their chief complaint at the Department of Psychiatry, St. Vincent's Hospital\n* Those capable of undergoing imaging studies, including Brain MRI and Amyloid PET CT\n* Individuals able to complete cognitive function tests, such as the Alzheimer's Disease Consortium test battery, K-MMSE, CDR, and GDS\n* Participants who can perform tests at the hospital's Smart Center, including the Short Physical Performance Battery and body composition analysis using direct segmental multi-frequency bioelectrical impedance analysis for sarcopenia\n* Individuals on acetylcholinesterase inhibitors (ACEi) or NMDA receptor antagonists who have maintained the same dosage and regimen for more than 3 months from the screening date.\n* Patients who are taking medications for cognitive function treatment other than acetylcholinesterase inhibitors and NMDA receptor antagonists (e.g., pregabalin, gabapentin, choline alfoscerate), as well as medications for chronic diseases such as antidepressants, antihypertensives, diabetes, hyperlipidemia, thyroid disorders, etc., must have maintained the same dosage and regimen for more than 1 month from the screening date.\n* Individuals with sufficient language proficiency to read and understand the informed consent document and respond to survey questionnaires\n\nExclusion Criteria:\n\n* Individuals with progressive mental or neurological disorders (including those with a history of psychotic disorders such as major depressive disorder, bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, or unspecified psychosis; patients currently experiencing major depressive disorder with psychotic symptoms; organic mental disorders; epilepsy or seizure disorders; patients currently suffering from eating disorders or obsessive-compulsive disorder).\n* Individuals with unstable or severe medical conditions.\n* Patients with severe snoring, REM sleep behavior disorder, or narcolepsy.\n* Illiterate individuals.\n* Individuals who, in the opinion of the investigator, are deemed unable to comply with the requirements of the study.\n* Patients currently taking sleeping pills within 2 weeks of the screening point.","60 Years","90 Years",{"count":139,"type":21},40,[24],"The goal of this clinical trial is to explore and verify the preventive effects of melatonin on the progression of Alzheimer's disease. The study aims to analyze the changes in blood biomarkers (phosphorylated tau, glial fibrillary acidic protein, neurofilament chain), various sleep-related subjective report questionnaire scores, physical performance, cognitive function scores and cerebellar volume change after three months of melatonin administration in patients with Alzheimer's-type mild cognitive impairment (MCI) accompanied by insomnia. The main questions it aims to answer are:\n\n1. Does melatonin administration alter the levels of blood biomarkers associated with Alzheimer's disease?\n2. What changes occur in sleep-related subjective report questionnaire scores and cognitive function scores following melatonin administration?\n3. Does melatonin administration effect on physical performance?\n4. Is there any relations between cognitive decline, phsycal performance and cerebellar volume change? We will compare the data collected before and after melatonin administration to determine its preventive effects on Alzheimer's disease progression.\n\nParticipants Will:\n\n1. Take melatonin every day for 3 months and Complete sleep-related subjective report questionnaires, neuropsychological assessments and physical performance test\n2. Visit the clinic at the initial visit and after 3 months for checkups and tests.\n3. Complete sleep-related subjective report questionnaires and neuropsychological assessments and physical performance test\n4. Provide blood samples for biomarker analysis.",[143,85,144,145,146,28],"Elderly","Melatonin","Cognitive Decline","Biomarker with Neurodegeneration Patients","2024-12-23",{"date":149,"type":40},"2025-01-03",{"date":151,"type":21},"2025-01-15",{"date":126,"type":21},{"name":154,"class":47},"Saint Vincent's Hospital, Korea"]